Status:
UNKNOWN
Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy
Lead Sponsor:
Guangdong Provincial People's Hospital
Conditions:
Type 2 Diabetes Mellitus
Nephropathy
Eligibility:
All Genders
30-70 years
Phase:
NA
Brief Summary
This is a prospective randomized controlled, open-labeled study to identify the efficacy of probucol in combination with valsartan in patients with Diabetes nephropathy. The reduction of urinary album...
Detailed Description
a prospective randomized controlled, open-labeled study in patients with Diabetes nephropathy * Arm 1: Valsartan + Probucol Valsartan (160mg/day) + Probucol (750mg/day) * Arm 2: Valsartan + Placebo V...
Eligibility Criteria
Inclusion
- Type 2 Diabetes nephropathy
- Urinary albumin excretion 1-3g/24hours
- Serum creatinine \< 3mg/dl
Exclusion
- Type 1 diabetes mellitus
- Renal diseases other than type 2 Diabetes nephropathy
- Renal artery stenosis
- Severe heart diseases
- Tuberculosis
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2017
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT00655330
Start Date
May 1 2008
End Date
May 1 2017
Last Update
August 24 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangdong General Hospital
Guangzhou, Guangdong, China, 510080